Covalent Modifiers

APRIL 7, 2024

Lavleen K. Mader and Jeffrey W. Keillor ACS Medicinal Chemistry Letters 2024 DOI: 10.1021/acsmedchemlett.4c00054 Experiments comprising a “pre-incubation” phase, where enzyme is incubated with inhibitor prior to the addition of assay substrate, are commonly used to evaluate covalent inhibitors, often via discontinuous or “endpoint” IC50 assays. However, due to the lack of mathematical tools to describe its biphasic time-dependent nature, this experiment has thus far been unable to provide kinact

150

150

Drug Patent Watch

APRIL 7, 2024

Annual Drug Patent Expirations for RELISTOR Relistor is a drug marketed by Salix Pharms and Salix and is included in two NDAs. It is available from one supplier.

Drugs 98

Drugs Marketing 98

Drug Patent Watch

APRIL 7, 2024

This chart shows the pharmaceutical companies with the most patents in Japan.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

APRIL 7, 2024

Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials